Search

Displaying results 3851 - 3860 of 5451 in total
  1. Drug

    Flutemetamol

    go.drugbank.com/drugs/DB15058
    Investigational

    Flutemetamol is under investigation in clinical trial NCT02353949 (Investigating the Clinical Consequences of Flutemetamol-PET-scanning).

  2. Drug

    Dezamizumab

    go.drugbank.com/drugs/DB15153
    Investigational

    Dezamizumab is under investigation in clinical trial NCT03417830 (Biodistribution of 89Zirconium-labelled GSK2398852 Using PET Imaging).

  3. Drug

    Propylene glycol

    go.drugbank.com/drugs/DB01839
    ApprovedInvestigational

    A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.

    Mixtures: Mycellcare iT s
  4. Drug

    Flupirtine

    go.drugbank.com/drugs/DB06623
    Investigational

    It was approved for the treatment of pain in 1984 in Europe. It is not approved for use in the U.S. or Canada, but is currently in phase II trials for the treatment of fibromyalgia.

  5. Drug

    L-cysteic acid

    go.drugbank.com/drugs/DB03661
    Experimental

    It occurs normally in the outer part of the sheep's fleece, where the wool is exposed to light and weather. … It is an amino acid with a C-terminal sulfonic acid group which has been isolated from human hair oxidized with permanganate.

  6. Drug

    Nisoxetine

    go.drugbank.com/drugs/DB09186
    Experimental

    It has been used to research obesity and energy balance, and exerts some local analgesia effects. … It was originally investigated as an antidepressant but has no current clinical applications aside from being a research standard SNRI.

  7. Drug

    Inbakicept

    go.drugbank.com/drugs/DB16479
    Investigational

    It is one of the active ingredients in Anktiva, a combination product also containing [nogapendekin alfa], where a single inbakicept is complexed with two nogapendekin alfa components. … [A263617, A263622] Inbakicept, in combination with nogapendekin alfa, mimics the actions of IL-15, stimulating the activation and proliferation of natural killer cells and CD8+ memory T cells, which also

  8. Drug

    Gemtuzumab ozogamicin

    go.drugbank.com/drugs/DB00056
    ApprovedInvestigational

    However, it was voluntarily withdrawn from the market in 2010 due to safety concerns, increased patient deaths and insufficient evidence of clinical benefit during confirmatory trials [L941]. … It is also indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory) [L941].

    Products: MYLOTARG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 5MG/VIAL, MYLOTARG 5 MG IV İNFÜZYONLUK ÇÖZELTİ HAZIRLAMADA KULLANILACAK KONSANTRE İÇİN TOZ, 1 FLAKON
  9. Drug

    GS030-DP

    go.drugbank.com/drugs/DB17847
    Investigational

    It is a component of GS030, an investigational optogenetic treatment, in combination with a medical device GS030-MD.[A259816, L46701] … It targets retinal ganglion cells that encodes a light-sensitive channelrhodopsin, ChrimsonR-tdTomato (ChR-tdT), delivered by an AAV2.7m8 vector.

  10. Drug

    PGX-100

    go.drugbank.com/drugs/DB06114
    Investigational

    It is a nearly nonanticoagulant heparin derivative that retains its anti-inflammatory activity. … It is developed for treatment of exacerbation of obstructive pulmonary disease (COPD) and for the prevention and treatment of cardiac ischemia reperfusion injury (following acute myocardial infarction